27th May 2020
Partnership enhances customer service and simplifies logistics of compound sourcing for scientists
BEACON, NEW YORK, USA (27 May, 2020) - MolPort Inc., the compound sourcing specialist, has announced the successful completion of 100 projects in partnership with BioAscent, a leading UK provider of integrated drug discovery services. Through their collaborative efforts, both companies significantly enhanced customer service by providing compounds in consistent formats and times, reducing variability, and simplifying the sourcing challenge for scientists world-wide.
The partnership, established in 2016, combines MolPort's online compound procurement platformconsisting of multiple high-quality compound suppliers, detailed product information, and its project management capabilitieswith BioAscent's expert team of scientists that provide on-demand, automated, quality-controlled compound dissolution and customized reformatting services. MolPort receives many samples from suppliers in multiple formats, including solids, dry film, and solution in vials or multi-well plates. In partnering with BioAscent, deliveries are now custom-designed so that customers receive all compounds in their specified, ready-to-use formats and layouts. Receiving these compounds without any specification uncertainties means scientists spend less time on the logistics of compound searching and ordering prior to researchconsiderably improving laboratory efficiency.
Reaching the 100-project milestone meant successfully fulfilling a diverse range of customer requests. Ranging from large to relatively small project sizes, different levels of project complexity and various timeframes, MolPort and BioAscent tailored their support to suit the needs of the customer. In one of the partnership's largest collaborative projects, both companies competently delivered a sizeable order of 143,531 compounds from 17 different suppliers, having managed all supplier communications, compound reformatting and project logistics. This was all carried out within eight weeksfrom initial idea to purchase a compound library to sending the compounds to BioAscent for reformatting and management. The customer required just one single point of contact and the collaboration ensured products were delivered on-time so that screenings were carried out as scheduled.
"We are extremely pleased to complete our 100th project with our drug development services partner, BioAscent, helping customers address their compound supply and logistics challenges", said Imants Zudans, CEO at MolPort. "Our long-term collaboration helps customers select the most reliable and cost-effective suppliers, enjoy on-time and on-budget delivery of complete compound libraries, and receive samples formatted to their exact and complex requirementsready for immediate screening. Our work removes administrative overhead, saving customers time and money, so that they can focus all their attention on the actual science itself."
BioAscent's Chief Operating Officer, Sylviane Boucharens, added: "We value our highly successful relationship with MolPort and are delighted to have reached this key milestone. Together we can provide an end-to-end service that includes compound searching, sourcing, acquisition, custom formatting, delivery and secure storage. This collaboration makes good use of BioAscent's state-of-the-art compound management, automated liquid handling, plating, QC and distribution capabilities. With our IT capabilities, we are able to ensure all samples and compound handling and plating activities are fully trackable and auditable."
MolPort covers many aspects of ordering, including access to commercially available compound data, customer communication and compound acquisition. Customers can choose from over 7.6 million compounds from major suppliers using MolPort's comprehensive database with continuously updated compound information, such as solubility data, to guide customers into choosing the right compounds for their research. The importance of providing solubility data was highlighted while working closely with customers who stated that a lack of compound solubility information can create challenges for the pharmaceutical industry, especially during compound screening.
The MolPort and BioAscent collaboration makes the lead discovery process considerably more efficient and less complex for any laboratories performing compound screenings. This partnership benefits not only biopharmaceutical companies, but also research institutions, universities, and biotech companies around the world.
Read more at www.molport.com/shop/case-study or contact email@example.com.
MolPort.com is a global trading platform selling over 7.6 million unique chemical stock compounds for research scientists. MolPort serves customers worldwide and has a global purchasing network. Our clientele includes 9 out of 10 top universities as well as a number of the top pharmaceutical companies, research institutions and biotech companies. We support chemistry-related research in over 50 countries.
Today millions of unique chemicals are made by thousands of companies and research institutions worldwide. Most of the chemical compounds remain difficult to locate and buy and therefore are inaccessible to many scientists. MolPort has created an easy-to-use marketplace for cost-efficient and centralized ordering of rare chemicals. By using MolPort chemical search, ordering and delivery services, scientists can focus their effort on new discoveries instead of spending valuable time synthesizing chemical compounds that may have already been created elsewhere.
BioAscent Discovery Ltd.
Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon/Merck Sharpe and Dohme (MSD) R&D site in Newhouse, Scotland. Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and data management. Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications. As part of its compound management service, BioAscent currently holds and manages over 1 million compounds for our customers, in both liquid and solid formats. Through the Compound Cloud service, the company provides rapid access to an IP-free library of ~125,000 lead like compounds in screening-ready format. Since 2013, the BioAscent team has been responsible for:
> 100 biochemical and biophysical assays for drug discovery projects
> 50 hit validation/characterization projects
> 30 hit-to-lead campaigns
> 80,000 screening plates delivered to our global customers/partners